Evidence map›Paper›PMID 33858039›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2021

[Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age].

N Peng, X L Dou, L Yu, Y Z Qin, H X Shi, Y Y Lai, Y Hou, X J Huang, Q Jiang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

N PengPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
X L DouPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
L YuPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
Y Z QinPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
H X ShiPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
Y Y LaiPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
Y HouPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
X J HuangPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
Q JiangPeking University People's Hospital, Peking} University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing} 100044, China.
Peking University · CN

Funding

National Natural Science Foundation of China 81770161, 81970140
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentAdultHumansImatinib MesylateMaleProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeAntineoplastic AgentsImatinib MesylateProtein Kinase InhibitorsAgeClinical characteristicsLeukemia, myeloid, chronicOutcomeTyrosine kinase inhibitors

Identifiers

PMID33858039
PMCPMC8071670
OpenAlexW3153661541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.